Skip to main content
. Author manuscript; available in PMC: 2026 Jan 17.
Published in final edited form as: Clin Cancer Res. 2025 Jul 15;31(14):3084–3095. doi: 10.1158/1078-0432.CCR-24-3168

Figure 3:

Figure 3:

Low-grade serous tumors with histologic transformation to TP53-wildtype higher-grade carcinoma components. (A-C) Case 13, showing admixture of low-grade (LG) and high-grade (HG) tumor components (A, 200X magnification). Higher magnification of low-grade serous carcinoma component with round, uniform nuclei showing mild atypia (B, 400X magnification) and high-grade serous carcinoma component, with severe nuclear pleomorphism and atypia, and abundant mitotic figures (black arrowheads). Representative “large” (red arrowheads) and “small” nuclei (blue arrowheads) demonstrate >3:1 nuclear size variation (C, 400X magnification). (D-E) Case 16, Low-grade serous carcinoma component (D, 400X magnification), and high-grade serous carcinoma component (E, 400X magnification), with immunohistochemistry showing p53 wildtype expression pattern (inset). (F) Case 1, with an indeterminate-grade serous carcinoma component, showing moderate nuclear atypia, with occasional large nuclei and abundant mitotic figures (400X magnification).